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Background: Promising results from previous studies using cell therapy
have paved the way for an innovative treatment option for amyotrophic
lateral sclerosis (ALS). There is considerable evidence of immune and
inflammatory abnormalities in ALS. Bone marrow mononuclear cells
(BMMNCs) possess immunomodulatory properties and could contribute
to slowing of disease progression.
Objective: Aim of our study was to evaluate the long‐term effect of
autologous BMMNCs combined with standard treatment on survival
duration in a large population and to evaluate effect of type of onset and
hormonal status on survival duration in the intervention group.
Methods: This controlled, retrospective study spanned over 10 years, 5
months; included 216 patients with probable or definite ALS, 150 in
intervention group receiving autologous BMMNCs and standard
treatment, and 66 in control group receiving only standard treatment.
The estimated survival duration of control group and intervention group
was computed and compared using Kaplan Meier analysis. Survival
duration of patients with different types of onset and hormonal status
was compared within the intervention group.
Results: None of the patients reported any major adverse events related
to cell administration or the procedure. Kaplan Meier analysis estimated
survival duration in the intervention group to be 91.7 months while 49.7
months in the control group (p = 0.008). Within the intervention group,
estimated survival was significantly higher (p = 0.013) in patients with
limb onset (102.3 months) vs. bulbar onset (49.9 months); premenopausal
women (93.1 months) vs. postmenopausal women (57.6 months) (p =
0.002); and preandropausal men (153.7 months) vs. postandropausal
males (56.5 months) (p = 0.006).
Conclusion: Cell therapy using autologous BMMNCs along with
standard treatment offers a promising and safe option for ALS with the
potential of long term beneficial effect and increased survival. Limb
onset patients, premenopausal women and men ≤ 40 years of age
demonstrated better treatment efficacy.
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1

Introduction

Amyotrophic lateral sclerosis (ALS) is the
commonest motor neuron disease in human
adults and is characterized by a rapid spread of
muscle weakness resulting from progressive
degeneration and loss of spinal cord, brainstem
and cortical motor neurons [1]. Extensive
preclinical studies have resulted in growing
knowledge and understanding of the under‐
lying disease process. However, it continues to
be a fatal disease with a mean survival of 2–3
years for bulbar onset cases and 3–5 years for
limb onset cases [2]. The available treatment is
essentially supportive with limited effect on
survival and quality of life of patients. The
underlying disease pathology is highly complex
and contributes to the unsatisfactory treatment
results. Moreover, only 5%–10% of cases are
familial. The only standard treatment, Riluzole
gives a very modest benefit of increasing the
patient’s lifespan by 2–3 months [3]. Edaravone
is another drug that has demonstrated limited
clinical efficacy in slowing down disease
progression [4, 5] and two studies failed to reach
statistical significance on the primary endpoint
[6, 7]. Moreover, studies on Edaravone are
limited to a follow‐up duration of 6 months.
Whether or not the benefits are sustained
beyond this time period and its effect on
survival is not known. Also, the procedure is
expensive and laborious considering the low
quality of life of these patients. Gene therapy
approaches are still in development phases [8].
In view of lack of available effective treatment
and on the other hand promising outcomes of
preclinical and clinical studies using stem cells
[9], cell therapy may serve as an innovative
approach for ALS treatment. Research has
shown a relationship between an inflammatory
pathway and disease progression in both animal
models [10] and human patients [11]. For any

treatment to be effective, slowing of the rapid
disease progression resulting from neuroin‐
flammation needs to be targeted. Owing to their
immunomodulatory properties, neuroprotective
and neurotrophic effects, bone marrow
mononuclear cells (BMMNCs) could contribute
to slowing disease progression. Previous studies
have demonstrated the beneficial effects of
BMMNCs in ALS [12–14]. These studies
demonstrated cell‐associated safety [12], the
ability of these cells to effectively modify the
motor neuron microenvironment [13] and
stabilization of the disease [14]. Our previous
study also demonstrated improved survival
duration in patients that had received BMMNCs
[15]. Moura et al. conducted a systematic review
and meta‐analysis to assess the efficacy of stem
cell therapy in preclinical and clinical studies
which showed improved survival and absence
of serious adverse events respectively [9]. The
studies, however, had small sample sizes and
did not assess the long‐term effect of cell
therapy on ALS patients.
The aim of this study was to evaluate the
long‐term effect of autologous BMMNCs along
with standard treatment on survival duration in
a larger population over an extended follow‐up
period. Also, within the intervention group, the
effect of treatment on onset type and hormonal
status were studied.

2
2.1

Materials and methods
Study design and patient selection

This is a retrospective controlled cohort study
including 216 patients. Patient records from
December 2008 to November 2020 were
gathered. All patients had been followed up
regularly either by a physical examination or
telephonically with attention to the progression
of primary symptoms and Revised ALS
Journal of Neurorestoratology

Journal of Neurorestoratology

Functional Rating Scale (ALS FRS‐R). Date and
cause of death if any were recorded during
telephonic follow‐ups. 150 patients that had
received cell therapy formed the intervention
group. 66 patients who did not receive cell
therapy formed the control group.
2.1.1

Inclusion criteria

Records of patients of age 35 years and above
with the diagnosis of definite or probable ALS
based on Revised El‐Escorial Criteria were
included for analyses.
2.1.2

Exclusion criteria

For record gathering, patients with a diagnosis
of progressive lateral sclerosis (PLS), progres‐
sive bulbar palsy (PBP), progressive muscular
atrophy (PMA), madras motor neuron disease
and other neuromuscular disorders that mimic
ALS symptoms were excluded.
Patients with the presence of acute infections
and other medical conditions such as anemia
(hemoglobin < 8 g/dl), bleeding tendencies,
malignancy and severe renal or liver dysfunc‐
tion had been excluded for intervention with cell
therapy.
2.2

Pre‐intervention assessment

As a routine, a comprehensive neurological
evaluation had been performed including a
functional assessment on ALS FRS‐R. Medical
fitness was established by routine biochemical,
serological and hematological tests. Electromyo‐
graphy/nerve conduction studies, electrocar‐
diogram, 2‐dimensional echocardiography, chest
X‐ray, arterial blood gas test. Morning plasma
total testosterone level tests were also performed
in male patients between October 2016 and
November 2020.
2.3

Intervention

Patient selection for the procedure was based on
the Revised World Medical Association Helsinki
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Declaration for Ethical Principles for Medical
Research involving human subjects [16]. Ethical
approval was obtained from the Institutional
Ethics Committee (IEC). Written informed
consent was obtained from each patient. 48 and
24 hours before transplantation, patients were
administered Granulocyte Colony Stimulating
Factor (GCSF) to promote mononuclear cell
mobilization.
2.3.1

Bone marrow aspiration

On the day of cell therapy, 100–120 mL of bone
marrow was aspirated using a bone marrow
aspiration needle from the iliac bone at the
anterior superior iliac spine, in the operation
theatre under aseptic conditions and under local
anesthesia.
2.3.2

Cell separation

This procedure was done in the stem cell
laboratory under aseptic conditions. Mononuclear
cells were isolated by density gradient
separation and were checked for viability count
using trypan blue vital dye mixed in 1:1
proportion and loaded on haemocytometer. This
was then confirmed on the TALI machine.
CD34+ count was checked by fluorescence‐
activated cell sorting (FACS) using CD34 PE
antibody.
2.3.3

Administration of BMMNC

In patients with a bulbar onset with absence of
limb and/or trunk involvement, all the cells
diluted in the patient’s cerebrospinal fluid (CSF)
were injected intrathecally. Until March 2017, 47
patients had received the cells, by both
intrathecal and intramuscular routes. In patients
with limb and/or trunk involvement, two‐thirds
of the separated mononuclear cells were injected
intrathecally at the level between 4th and 5th
lumbar vertebrae. One‐third of the amount was
diluted in the patient’s CSF and injected
intramuscularly at the motor points of muscles
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that were weak and of functional importance.
Since no significant benefit was observed in the
injected muscles, targeting all the separated cells
to the brain and spinal cord by intrathecal route
was considered a more viable option. Hence, all
patients after March 2017, received BMMNCs
intrathecally only. Patients were simultaneously
administered 20 mg/kg body weight methyl‐
prednisolone in 500 mL ringer lactate intraven‐
ously to reduce the immediate inflammation
and to enhance cell survival.
Cell therapy was followed by an individ‐
ualized multidisciplinary neurorehabilitation
program over the next 4‐day hospital stay. This
included physiotherapy, occupational therapy,
speech therapy and psychological counseling.
Patients were monitored for immediate and
long‐term adverse events.
A detailed home program was prescribed at
discharge and patients were advised to follow
up every 3 months. Standard Riluzole
medication was continued. Lithium 300 mg
once/twice a day for 6 weeks was prescribed, to
bring levels between 0.5–0.8 mEQ/L, to those
who could tolerate it. Other medications
included medications to control symptoms such
as drooling, spasticity, etc.
Post‐October 2016, patients with levels below
mean age‐matched healthy levels of plasma
testosterone levels were prescribed injection
testosterone enanthate 250 mg, once a month for
3 months.
2.3.4

Follow up

Patients had been followed up regularly either
physically or telephonically until November
2020. A detailed neurological assessment was
performed at each physical and/or telephonic
follow up follow up. Symptomatic or ALS FRS‐R
change and the date of death, wherever
applicable, had been recorded.
2.4
2.4.1

Outcome measures and statistical analysis
Demographic assessment

Baseline information about age at disease onset,

gender, percentage of patients that had taken
Edaravone injections and patients that had a
limb or bulbar onset for the treatment and
control groups was obtained. Within the
intervention group, the percentage of patients
that had received testosterone enanthate
injections and lithium was obtained.
The intervention group was subdivided based
on the type of onset, as bulbar and limb onset;
hormonal status of women, as premenopausal
and post‐menopausal women and; hormonal
status of men, as preandropausal men (≤ 40
years of age) and postandropausal men (> 40
years of age). Since testosterone levels decline
after the age of 40 years, it was chosen for
studying the effect of hormones on survival
duration in males [17, 18].
2.4.2

Adverse events

Patients had been monitored for immediate and
long‐term adverse events. Adverse events were
categorized as procedure‐related or cell‐related.
Percentage of patients that exhibited adverse
events were computed (Table 2).
2.4.3

Percentage distribution of mortality

Percentage mortality was compared between
intervention and control groups. Within the
intervention group, percentage mortality in the
subgroups (premenopausal women, postmen‐
opausal women, preandropausal and postand‐
ropausal) was calculated as: number of deaths in
each group/total number of deaths in the
intervention group × 100%.
2.4.4

Survival duration

Comparison of survival duration. Survival
duration was used as an outcome measure.
Time in months until mortality was obtained for
the intervention and control groups and
compared using Kaplan–Meier survival analysis.
Also, within the intervention group, months
Journal of Neurorestoratology
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until mortality for bulbar and limb onset
patients, pre‐ and post‐menopausal women, pre‐
and post‐andropausal, were computed and
compared using Kaplan–Meier survival analysis.
2.4.5

Statistical analysis

Demographic data analysis. Descriptive statistics
were used for demographic data. Data are
described using means and standard deviation
and percentages.
Survival

analysis.

Kaplan–Meier

survival

analysis was used to estimate the survival
duration. Comparison between the groups was
made using a log‐rank test. All the statistical
tests were performed with a significance level of
p‐value less than 0.05. SPSS (version 20.0) was
used for the analysis.
Figure 1 shows the patients included in the
study and the outcome measures used.

3
3.1

Results
Demographic assessment

The demographic description has been shown

Fig. 1 Study protocol and outcome measures.

in Table 1.
3.2

Adverse events

None of the patients reported any major adverse
events related to stem cells or the procedure. All
the adverse events were mild and transient and
resolved with medical treatment. The common
minor adverse events included back pain or
pain at the injection site, constipation, headache,
loose motions, nausea and/or vomiting, and
pain at the aspiration site (Table 2).
3.3

Percentage distribution of mortality

The total number of deaths was 102 of 150 (68%)
patients in the intervention group and 52 of 66
(78.8%) patients in the control group. The mean
survival duration in the intervention group was
56.1 months (minimum: 8 months; maximum:
433 months). The mean survival duration in the
control group was 43.8 months (minimum: 3
months; maximum: 121 months).
Percentage mortality in the premenopausal,
postmenopausal, preandropausal and postand‐
ropausal subgroups within the intervention
group are shown in Table 3.
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Table 1

Demographic data of the study population.
Demographics

Intervention group

Control group

51 (34%)
99 (66%)

19 (28.79%)
47 (71.21%)

Intramuscular Injection
Patients received intramuscular transplantation of cells (percentage)
Patients not received intramuscular transplantation of cells (percentage)

47 (31.3%)
103 (68.7%)

0 (0)
66 (100%)

Lithium
Patients prescribed lithium (percentage)
Patients not prescribed lithium (percentage)

125 (83.3%)
25 (16.7%)

0 (0)
66 (100%)

Edaravone
Edaravone taken (percentage)
Edaravone not taken (percentage)

19 (12.7%)
131 (87.3%)

4 (6.01%)
62 (93.94%)

Testosterone
Testosterone injection prescribed (percentage)
Testosterone injection not prescribed (percentage)

23 (23.2%)
76 (76.8%)

0 (0)
66 (100%)

Type of Onset
Patients with bulbar onset (percentage)
Patients with limb onset (percentage)

34 (22.7%)
116 (77.3%)

16 (24.2%)
50 (75.8%)

The average age at onset in years (SD)

50 (10)

54 (9)

Gender
No. of females (percentage)
No. of males (percentage)

Table 2

Adverse events observed in the post‐intervention period.
Adverse events

Percentage adverse events
immediately post‐intervention

cell‐related adverse events

Minor
Spinal headache

13.3 %

Nausea and/or vomiting

7.0 %

Pain at the aspiration site

3.8 %

Backache/pain at the injection site

10.1 %

Fatigue

2.7 %

Constipation

8.2 %

Loose motion

1.9 %

None

Major
Sudden onset of respiratory discomfort

None

Neurological deficits

None

Paresthesia/loss of sensation in lower limb

None

Cardiac failure

None

Hematoma at the injection site

None

None

Table 3 Percentage distribution of deaths within intervention group in premenopausal and postmenopausal women,
preandropausal and postandropausal men.

Distribution of
mortality

Premenopausal women

Postmenopausal women

Preandropausal men

Postandropausal men

6 (5.9%)

31 (30.4%)

14 (13.7%)

51 (50%)

Journal of Neurorestoratology
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urvival analyses

3.4.1 Comparison of survival duration between
intervention and control group
The mean survival duration in the intervention
group was estimated to be 91.7 months and in
the control group, it was estimated to be 49.7
months. The survival duration in the
intervention group was estimated to be 42
months higher than in the control group (p =
0.008) (Table 4, Fig. 2).
3.4.2 Comparison of survival duration between
subgroups within the intervention group
The estimated survival duration for limb onset
Table 4 Kaplan–Meier analysis of survival duration for
patients with and without cell therapy.

Estimated
survival duration
(months)

Intervention
group

Control
group

p value

91.7

49.7

0.008*

*Indicates a statistically significant difference between the
groups.

patients (102.3 months) was significantly higher
(p = 0.013) than those with bulbar onset (49.9
months). Likewise, survival duration was
significantly higher (p = 0.002) in premenopausal
women (93.1 months) when compared with
postmenopausal women (57.6 months) and in
preandropausal men (153.7 months, p = 0.006)
compared to postandropausal men (56.5 months)
(Table 5, Fig. 3).

4
4.1

Discussion
Management of ALS

With an incidence of between 1.2 and 4.0 per
100,000 persons per year, ALS continues to be a
fatal neuromuscular disease [19]. The only
standard treatment, Riluzole gives a very
modest benefit of increasing the patient’s
lifespan by 2–3 months [3]. Edaravone is another
drug that has received FDA approval, but
studies are limited to a follow‐up duration of 6
months. Whether or not the benefits are sustained
Table 5 Effect of prognostic factors on survival duration
within the intervention group.
Prognostic factors

Onset type
Bulbar onset
Limb onset
Hormonal status
(Women)
Premenopausal women
Postmenopausal
Women
Fig. 2 Kaplan–Meier graph showing comparison of the
estimated survival duration in intervention and control groups.
Mean estimated survival duration was 91.7 months in the
intervention group while in the control group it was 49.7
months (p = 0.008*). *Indicates a statistically significant
difference between the groups.

Hormonal status
(Males)
Preandropausal men
Postandropausal men

Estimated survival
duration (months)
as calculated by
Kaplan–Meier
survival analysis

Statistical
significance

49.9
102.3

0.013*

93.1
57.6

0.002*

153.7
56.5

0.006*

*Indicates a statistically significant difference between the
groups.
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Fig. 3

Comparison of survival duration among the subgroups within the intervention group. (A) Bulbar onset vs. limb onset groups; (B)

premenopausal vs. postmenopausal women; and (C) preandropausal vs. postandropausal men.

beyond this time period and its effect on
survival is not known. Gene therapy approaches
are still in development phases.
Our study demonstrated that administration
of autologous BMMNC possesses long term
safety and efficacy. In our study, we found that
there was a significantly higher survival
duration of 42 months in patients that received
cell therapy and lithium along with standard
treatment as compared with patients that
received standard treatment only.
4.2 Effect of onset type, age, and hormonal
status on survival duration
Within the intervention group, limb onset
patients, premenopausal women and preandro‐
pausal men had significantly higher survival
duration compared to the bulbar onset,
postmenopausal women and postandropausal
men at disease onset respectively. Previous
studies have shown patients with bulbar‐onset
to have lower survival than patients with the
limb‐onset disease, and this, independent of the
age factor [20–24]. Increasing age is also a
known risk factor for ALS. The average age of
disease onset is 61.8 ± 3.8 years (ranging from
54–67 years of age) [25]. At higher ages, the
difference in the proportion of males and
females with the disease drops significantly. In
the younger age groups, the male/female ratio of
ALS incidence is about 2.5:1 but in the older age

group it has shown to decline to 1.4:1 [26]. In
ages above 60 years, the male/female ratio of
ALS incidence decreases further and becomes
1:1 [27]. Our earlier studies showed better
treatment outcome in premenopausal women
and in patients younger than age 50 years of age
[15, 28]. This suggests a possible protective role
of sex hormones in the younger age groups.
Several studies have suggested a role of sex
hormones in the pathogenesis of the disease.
Estradiol has shown to have a direct protective
effect on spinal motor neurons by preventing
glutamate and nitric oxide‐induced neuron
death [29]. Ovariectomy in mice models of ALS
caused an acceleration of the disease
progression [30]. Further, when these mice were
subsequently treated with 17β‐estradiol, disease
progression was slowed. Likewise, progesterone
levels have shown to possess a positive
correlation with survival and length of time
between disease onset and diagnosis both of
which are factors of a better prognosis [31].
Treatment of animal models of the disease with
progesterone showed less severe symptoms and
even reversal of histopathological abnormalities
as compared to those mice that didn’t receive
progesterone [32, 33]. Though in humans, the
association between estrogen and ALS incidence
has not been proven and the results of studies
are conflicting [34, 35], our present study
showed better survival duration in premeno‐
Journal of Neurorestoratology
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pausal women than postmenopausal women
with a difference of 35.5 months which was
statistically significant.
Androgens have also been suggested to have
a possible role in the pathogenesis of ALS.
Deficient synthesis of testosterone, ADIONE, its
precursor and 5α‐DHT was observed in testes of
animal models of ALS [36]. Further, low plasma
testosterone levels were shown to correlate with
low testosterone levels in the spinal cord.
Administration of anti‐androgen in mice
resulted in acceleration of disease onset and
motor deficits [37]. In our earlier study
including patients with ALS, a correlation
between lower levels of plasma testosterone and
disease severity on ALS FRS‐R scale and King’s
staging was seen [38]. Therefore, post‐October
2016, patients with levels below mean age‐
matched healthy levels of plasma testosterone
levels were prescribed injection testosterone
enanthate 250 mg, once a month for three
months. In the present study also, we found
better survival duration in men aged 40 years
and below as compared with men above 40
years of age. The difference of 97.2 months was
statistically significant.
4.3 Pathophysiology and mechanism of action
of BMMNCs in ALS
The discovery of mutations in Cu/Zn superoxide
dismutase (mSOD1) as the commonest cause of
familial ALS led to the development of
experimental animal models and an increase in
the understanding of the underlying pathoge‐
nesis [39]. Mitochondrial dysfunction, increased
reactive oxygen species (ROS), misfolded and
aggregated proteins, and dysfunction of the
ubiquitin proteasome pathway have been
suggested as the possible events that promote
neurodegeneration [40]. Though the exact cause
of motor neuron degeneration is still unclear,
considerable evidence exists to demonstrate the
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presence of immune and inflammatory
abnormalities in ALS. Irrespective of the cause
of the disease, neuroinflammation at the sites of
motor neuron injury is evident as the presence
of microglial activation, astrogliosis and
monocyte and T‐cell infiltration. The early
immune responses to signals of motor neuron
injury are to rescue and repair damaged tissue
[41]. However, as the disease progresses, there is
a shift from the beneficial M2 microglia and
regulatory T‐cells to the deleterious effect of
immune responses involving activated M1
microglia. Activated M1 microglia is cytotoxic
due to release of more pro‐inflammatory factors
such as tumor necrosis factor (TNF)‐α,
interleukin (IL)‐1β and nitric oxide (NO) and
ROS which is neurotoxic and mediate motor
neuron death [42–44]. The pro‐inflammatory
factors further activate the microglia in a
self‐propagating cycle causing a further increase
in neurotoxicity [45]. Activated microglia also
show enhanced phagocytic activity and can
phagocytose apoptotic neural cells as well as the
normal neurons [46]. Microglial activation is
more prolonged and to a greater degree in the
aged brains as compared to the adult brain [47].
Thus, uncontrolled inflammatory responses
mediated by activated microglia can have
detrimental effects, particularly in the older age
groups. The M2 microglia, on the other hand,
are anti‐inflammatory and neuroprotective [48].
In order to effectively alter the rapid disease
progression, neuroinflammation needs to be
targeted. Multiple compounds with anti‐
inflammatory properties have been tested in
clinical trials but unfortunately, have failed to
show positive results [49–55]. Inflammation may
be better modulated by cell therapy. Adult
BMMNCs contain a mixture of cells including
hematopoietic progenitor cells, lymphoid cells,
monocytes, macrophages [56] and cells from the
non‐hematopoietic lineages including, side
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population cells [57], mesenchymal stromal cells
[58], very small embryonic stem cells [59],
multipotent adult progenitor cells [60], heman‐
gioblasts, endothelial progenitor cells [61] and
tissue committed stem cells [62]. BMMNCs have
demonstrated the ability to decrease proinflam‐
matory cytokines and increase antiinflammatory
cytokines [63]. Also, mesenchymal stem cells can
alter the polarization status of microglia as
evidenced by an increased expression of M2
markers and a decreased expression of M1
markers, in vitro [64–67]. Further, bone marrow
cells release a host of trophic factors such as
nerve growth factor (NGF), brain‐derived
neurotrophic factor (BDNF) and glial cell line
derived neurotrophic factor (GDNF) [68–71]
many of which have shown to alleviate motor
neuron degeneration in animal models [12, 72].
GDNF has shown to protect neurons from
entering apoptosis [73, 74]. Blanquer et al.
demonstrated evidence of decreased ubiquitin
deposits in the spinal motoneurons post
autologous BMMNC transplantation [13].
BMMNCs may significantly increase the level of
vascular endothelial growth factor (VEGF) [75].
Oosthuyse et al. implicated VEGF in the
pathogenesis of ALS [76]. VEGF is a key
angiogenic factor that also confers neuroprotec‐
tion by the promotion of neuron survival [76–79]
and neurogenesis by neuronal migration, axon
guidance [80, 81] and increases life expectancy
in animal models of ALS [82–84].
4.4

Rationale for lithium administration

Lithium has demonstrated neuroprotective
effects in animals and humans. Preclinical
studies have shown improved motor function in
animal models of ALS post‐treatment with
lithium [85]. Lithium has shown to promote
neuronal survival, enhance mitochondrial
respiratory rate, decrease oxidative stress and
modulation of calcium influx in mitochondria

[86–92]. It has also shown to induce synapto‐
genesis [93]. A clinical study demonstrated the
safety and efficacy of lithium in slowing disease
progression and improving survival in ALS
patients [94]. Our previous pilot study also
demonstrated higher survival in patients that
received lithium as compared to those who did
not receive lithium [15]. Patients were hence
prescribed short term lithium.
Route of administration
Intrathecal application of cell therapy offers
several advantages. It is less invasive and allows
for a simple procedure. It is thus possible to
perform the procedure multiple times. Also,
since ALS involves widespread degeneration
along the entire length of the neural axis,
intrathecal application of stem cells may be a
more viable option. Due to the dynamics of CSF
flow, it may be a more effective method to
influence multiple brain and spinal cord areas
that are affected by the disease [95]. Wu et al.
and Bai et al. reported that cells delivered
through the CSF migrate to the injury site in the
spinal cord [96, 97]. Additionally, intra‐arterial
and intravenous administration results in the
trapping of the injected cells in organs such as
the lungs and liver [98, 99]. This can be avoided
using intrathecal application of stem cells.
Application of cells into the muscles may be
advantageous as trophic factors released by
stem cells may provide support to the
neuromuscular junctions [100]. Intramuscular
injection of bone marrow derived stem cells has
shown to cause an increase in size of endplates
and a resultant greater survival of motor
neurons in animal models of motor neuron
degeneration [101]. However, in our initial
experience of 47 patients, additional intramuscular
injection of bone marrow stem cells did not
demonstrate any significant improvement in
Journal of Neurorestoratology
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strength of those muscles. Hence, intramuscular
injections were discontinued. Since the disease
involves progressive degeneration along the
entire length of the neural axis, targeting all the
separated BMMNCs to the brain and spinal cord
by intrathecal route may be more effective and
beneficial. Hence, after March 2017, all patients
in the intervention group were given cells by
intrathecal route only.
4.5

Pre‐clinical studies

Intraperitoneal administration of bone marrow
cells significantly delayed disease onset and
increased survival in SOD1 mice [102].
Improved motor function, attributed to the
trophic factors produced directly or indirectly
by transplantation of bone marrow hemato‐
poietic cells into the spinal cord of a mouse
model of ALS, was reported by Cabanes et al.
[73]. Intravenous combined with intramuscular
administration of BMMNCs, delayed onset of
functional deficits, decreased microgliosis in the
lumbar ventral horn and increased the number
of partially innervated neuromuscular junction
[103]. Similarly, intraspinal administration of
these cells in a mouse model of ALS delayed
disease progression in the presymptomatic
phase [104].
4.6

Clinical studies

Studies have shown autologous BMMNC
transplantation to be safe and a promising
treatment approach for ALS. In our previous
study, survival was higher in the group of
patients that underwent autologous BMMNCs
intrathecally than in the control group of
patients [15]. It was also higher than the survival
duration of ALS patients in previous
epidemiological studies. In another study by
Prabhakar et al., stabilization of disease was
observed, with no significant decline in ALS
FRS‐R score over a one‐year follow‐up duration,

127

following intrathecal administration of autolo‐
gous bone marrow derived stem cells [14]. A
study by Martinez et al. suggested slower
disease progression in ALS patients during a
one year follow up post intrathecal trans‐
plantation of bone marrow derived mono‐
nuclear cells [105]. In this study, a total decrease
of 4 points in the ALS FRS‐R score at one year
was noted against the usual average decline of
13.32 points. In a study by Deda et al., 9 of 13
ALS patients showed improvement while 1
patient remained stable on Norris scale and
electroneuromyography, post‐surgical trans‐
plantation of BMMNCs into the anterior part of
the spinal cord, over 1 year follow up duration
[106]. Blanquer et al. demonstrated that
BMMNCs modified the motoneuron microen‐
vironment and favoured their survival as was
evident by spinal cord pathological analysis that
showed a lack of signs of motoneuron
degeneration in the treated segments [13].
Spinal transplantation of these cells also
demonstrated respiratory stability over at least 1
year follow up duration. Also, the respiratory
events during sleep, in these patients remained
at levels lower than patients (receiving standard
medical care only) with similar disease duration
[107]. Systematic review and meta‐analysis by
Moura et al. showed improved survival and
absence of major adverse effects in preclinical
and clinical studies [9].
Our results and previous studies demonstrate
the safety and potential benefits of autologous
BMMNCs in ALS. Considering the underlying
disease pathology, transplanting these cells, that
have the potential of detoxifying the microen‐
vironment around motoneurons, may be of
clinical significance.
4.7

Limitations

There were some limitations to the study.
Although this was a controlled study, it was
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retrospective and not randomised. Not all
patients in the intervention group had received
lithium. Standard treatment had changes in the
10‐year study duration. With the U.S. Food and
Drug Administration approval of Edaravone for
ALS treatment, some patients from the
intervention group received the treatment.
However, this was also the case for the patients
in the control group. Post‐October 2016 in the
intervention group, males with levels below
mean age‐matched healthy levels of plasma
testosterone levels were prescribed injection
testosterone enanthate 250 mg, once a month for
three months. Also, intramuscular injection of
stem cells was discontinued post March 2017.

5

Conclusion

Cell therapy using autologous BMMNCs along
with standard treatment offers a promising and
safe option to ALS with the potential to delay
disease progression and increase survival with
sustained benefits over a long‐term duration.
Survival duration in the intervention group was
estimated to be 42 months higher than in the
control group. Survival was significantly higher
in patients with limb onset, premenopausal
women and preandropausal men as compared
to patients with bulbar onset, postmenopausal
women and postandropausal men. The role of
hormones in the disease pathology in humans
and hormone therapy as an adjuvant to cell
therapy and standard treatment needs to be
considered.
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